- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00474916
Neuropathic Pain in Patients With Cancer
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Neuropathic pain is a type of pain that results from nerve damage and is characterized by an abnormal hypersensitivity to harmless as well as harmful stimuli. This type of pain is extremely difficult to manage, fails to respond to standard analgesic medications or interventions, and often gets worse instead of better over time. Current approved therapeutic agents often have intolerable side effects and limited efficacy. Thus, there is an urgent need to develop safe and effective drugs to treat neuropathic pain.
Study DTCL100 will be conducted at multiple centers and will enroll patients that have advanced cancer AND neuropathic pain that has not responded well to previous treatment. Eighteen patients will be randomly assigned to receive up to 8 doses of active drug (KRN5500) or placebo. A maximum of 8 doses will be administered weekly over a 10 week period. Patients are encouraged to complete at least 4 treatment visits before a decision is made to complete the full 10 weeks of treatment and the 1 month followup period.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Rio Piedras, Porto Rico, 00921
- Dr. Rivera-Colon
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90025
- Cancer Institute Medical Group
-
Los Angeles, California, États-Unis, 90027
- Ghassan Al-Jazayrly, M.D., Inc.
-
Orange, California, États-Unis, 92868
- University of California / Irvine Chao Family Comprehensive Cancer Center
-
-
Florida
-
Jupiter, Florida, États-Unis, 33477
- Keog Pharma, Inc.
-
-
Louisiana
-
Covington, Louisiana, États-Unis, 70433
- Hematology And Oncology Specialists, Llc
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21229
- St. Agnes Healthcare, Inc
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
-
New Jersey
-
East Orange, New Jersey, États-Unis, 07018
- East Orange VA Medical Center
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, États-Unis, 27103
- Carolina Pain Institute, PA
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 years or older
- Diagnosis of advanced or recurrent cancer
- No options for curative chemotherapy, but palliative chemotherapy allowed under certain conditions
- Refractory neuropathic pain rated 4 or greater on 0-10 scale and failure to respond to 2 commonly used treatments
- If taking opioids for pain, stable regimen over past week before enrolling
- Karnofsky performance status of 40 or more
- Females must be sterile or post-menopausal
Exclusion Criteria:
- Radiation to site of neuropathic pain for past 4 weeks
- Major surgery within past 2 weeks
- Liver function and other key labs outside normal parameters
- ECG showing significant abnormality
- Myocardial Infarction (heart attack) within past 6 months
- History of interstitial lung disease
- History of severe allergic reaction to drugs containing polysorbate 80
- Other investigational drug within 2 weeks or 5 half-lives (whichever is longer
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: KRN5500
KRN5500 escalating dose of .6,
1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
|
Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo .
The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
|
Comparateur placebo: Normal Saline
Placebo consists of IV infusion of normal saline
|
Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo .
The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Normal Saline given as dose escalation for placebo
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Average pain intensity over the previous 24 hours as measured by a numeric rating scale (NRS) ranging from 0 to 10 where 0 represents "no pain" and 10 represents the "worst possible pain."
Délai: Weekly for 10 weeks plus 30 day followup
|
Weekly for 10 weeks plus 30 day followup
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Physical Examination, Vital signs and body weight, Electrocardiogram, Laboratory parameters, Adverse events, Clinical Opiate Withdrawal Scale, rescue medication, Proportion of patients who achieved a 33% reduction in pain intensity
Délai: Weekly for 10 weeks plus 30 day followup
|
Weekly for 10 weeks plus 30 day followup
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Richard Penson, MD, MRCP, Massachusetts General Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- DTCL100
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Douleur neuropathique
-
Evergrain, LLCINQUIS Clinical Research Ltd.ComplétéSatiété du pain riche en fibres et riche en protéinesCanada
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceComplétéChangements de poids corporel | Modification alimentaire | Microbiote gastro-intestinal | Pain | Tests hématologiquesIsraël
-
University of BergenUniversity of Leipzig; Chalmers University of Technology; Nofima; Paderborn UniversityComplétéHyperglycémie | Prédiabète | Contrôle glycémique | PainNorvège
-
Ege UniversityComplétéObésité | Index glycémique | Glucose sanguin | PainTurquie
Essais cliniques sur KRN5500
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)ComplétéTumeur solide adulte non précisée, protocole spécifiqueÉtats-Unis